Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Placebo, Etavopivat A 200 mg
Novo Nordisk A/S
Sickle cell disease
1 trial -
Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10144
Novo Nordisk A/S
Overweight or obesity, and knee osteoarthritis
1 trial -
Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets
Novo Nordisk A/S
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
1 trial -
Rybelsus 7 mg tablets, Placebo (semaglutide) tablet, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets
Novo Nordisk A/S
Type 2 diabetes
1 trial -
Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets
Novo Nordisk A/S
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
1 trial -
Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290
Novo Nordisk A/S
Type 2 diabetes
1 trial -
Semaglutide B 1.34 mg/mL PDS290 3.0 mL, Wegovy 2.4 mg solution for injection in pre-filled pen, Pre-filled syringe (glass) in a pre-filled pen: Semaglutide placebo Ia DV3396 pen-injector, 0.5 mL Semaglutide placebo Ib DV3396 pen-injector, 0.75 mL, Semaglutide B 0.68 mg/mL PDS290 1.5 mL, Semaglutide D 1.0 mg/mL DV3396, Semaglutide D 2.0 mg/mL DV3396, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Semaglutide B 3.2 mg/mL PDS290 3.0 mL
Novo Nordisk A/S
Non-alcoholic steatohepatitis (NASH)
1 trial -
Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen
Novo Nordisk A/S
Growth Hormone Deficiency in children
1 trial -
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143
Novo Nordisk A/S
Participants with overweight or obesity, and type 2 diabetes
1 trial -
cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide
Novo Nordisk A/S
Obesity
1 trial -
cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide
Novo Nordisk A/S
Cardiovascular disease
1 trial -
cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, METFORMIN , INSULIN DEGLUDEC , INSULIN (HUMAN) , INSULIN GLARGINE , cagrilintide semaglutide, INSULIN DETEMIR , Placebo + Placebo
Novo Nordisk A/S
Type 2 diabetes
1 trial -
cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide
Novo Nordisk A/S
Overweight and obesity and type 2 diabetes
1 trial -
cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo
Novo Nordisk A/S
Type 2 diabetes
1 trial -
cagrilintide, Placebo, cagrilintide, cagrilintide, cagrilintide
Novo Nordisk A/S
Overweight and obesity
1 trial -
cagrilintide, cagrilintide, cagrilintide, cagrilintide, Placebo
Novo Nordisk A/S
Overweight and obesity
1 trial -
coramitug C 10035, liquid dosage form in 20 mL vials with 11 extractable volume
Novo Nordisk A/S
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
1 trial -
ziltivekimab, Placebo (ziltivekimab C)
Novo Nordisk A/S
Heart failure with mildly reduced or preserved ejection fraction and systemic inflammation
1 trial -
ziltivekimab, Ziltivekimab
Novo Nordisk A/S
The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction
1 trial -
Decitabine/Tetrahydrouridine A 5/250 mg, Siklos 1 000 mg film-coated tablet., Placebo (NDec)
Novo Nordisk A/S
Sickle cell disease
1 trial -
GADOTERIC ACID , PARACETAMOL , coramitug, CETIRIZINE , SODIUM CHLORIDE
Novo Nordisk A/S
Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
1 trial -
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.
Novo Nordisk A/S
Heart Failure with Preserved Ejection Fraction and Left Ventricular Hypertrophy.
1 trial -
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants with Heart Failure with Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy.
Novo Nordisk A/S
Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left Ventricular Hypertrophy.
1 trial -
Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide
Novo Nordisk A/S
Type 2 diabetes and painful diabetic peripheral neuropathy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources